Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Long-term additional lamivudine therapy enhances durability of lamivudine-induced HBeAg loss: a prospective study.

Journal of hepatology - 1 Oct 2003

Ryu Soo Hyung, Chung Young-Hwa, Choi Min Hee, Kim Jeong A, Shin Jung Woo, Jang Myoung Kuk, Park Neung Hwa, Lee Han Chu, Lee Yung Sang, Suh Dong Jin

Abstract excerpt

BACKGROUNDS/AIMS: In the treatment of chronic hepatitis B (CHB) with lamivudine, adequate duration of the therapy remains to be determined. In this prospective study, the authors intended to investigate whether long-term additional administration of lamivudine might enhance the durability of lami...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Drug Administration Schedule
Share to Hepatitis B, Chronic
Share to Hepatitis B e Antigens

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Hepatitis B virus

Share to Lamivudine

Share to Recurrence

Share to Reverse Transcriptase Inhibitors

Share to Viral Core Proteins

Source

Identifiers

PMID: 12971973
DOI: 10.1016/s0168-8278(03)00394-5

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 1 Sept 2026. Prepared record publication-12971973-2026-09-01.1. Manifest publication-graph-cohort-2026-09-01.1.

Source receipt: PubMed via Helena Literature Corpus, retrieved 1 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Long-term additional lamivudine therapy enhances durability of lamivudine-induced HBeAg loss: a prospective study.PMID 12971973Read ↗

Determinants for sustained HBeAg response to lamivudine therapy.Semantic proximity Read ↗

Favorable efficacy of long-term lamivudine therapy in patients with chronic hepatitis B: an 8-year follow-up study.Semantic proximity Read ↗

Quantitative polymerase chain reaction assay for serum hepatitis B virus DNA as a predictive factor for post-treatment relapse after lamivudine induced hepatitis B e antigen loss or seroconversion.Semantic proximity Read ↗

Extended lamivudine treatment in patients with chronic hepatitis B enhances hepatitis B e antigen seroconversion rates: results after 3 years of therapy.Semantic proximity Read ↗

Adefovir plus lamivudine are more effective than adefovir alone in lamivudine-resistant HBeAg- chronic hepatitis B patients: a 4-year study.Semantic proximity Read ↗

Efficacy of long-term lamivudine monotherapy in patients with hepatitis B e antigen-negative chronic hepatitis B.Semantic proximity Read ↗

Analysis of clinical, biochemical and viral factors associated with early relapse after lamivudine treatment for hepatitis B e antigen-negative chronic hepatitis B patients in Taiwan.Semantic proximity Read ↗

Long-term effects of lamivudine treatment in Japanese chronic hepatitis B patients.Semantic proximity Read ↗

Virological and biochemical relapse after discontinuation of lamivudine monotherapy for chronic hepatitis B in Japan: comparison with breakthrough hepatitis during long-term treatment.Semantic proximity Read ↗

Long-term lamivudine treatment for chronic hepatitis B in Japanese patients: a project of Kyushu University Liver Disease Study.Semantic proximity Read ↗

Efficacy and tolerability of long-term therapy using high lamivudine doses for the treatment of chronic hepatitis B.Semantic proximity Read ↗

Long-term safety of lamivudine treatment in patients with chronic hepatitis B.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.